Concord Biotech Limited

Concord Biotech Limited

  • IPO Date04 Aug, 2023 to 08 Aug, 2023
  • Listing Date18 Aug, 2023
  • Face Value₹1 per share
  • Issue Price₹705 to ₹741 per share
  • Lot Size20 Shares
  • Minimum Investment₹14,820
  • Listing AtBSE, NSE
  • Total Issue Size2,09,25,652 Shares
    (aggregating up to ₹1550.59 Cr)
  • Fresh Issue-
  • Offer for Sale2,09,25,652 Shares
    (aggregating up to ₹1550.59 Cr)
  • Issue TypeBook Built Issue IPO
  • Share holding pre issue10,46,16,204
  • Shareholding post issue10,46,16,204
IPO Dates

Closing Date

08 Aug, 2023

Initiation of Refunds

17 Aug, 2023

Listing Date

18 Aug, 2023

04 Aug, 2023

Opening Date

11 Aug, 2023

Basis of Allotment

17 Aug, 2023

Credit of Shares

UPI Mandate Expiry Date:08 Aug, 2023

Concord Biotech Limited Lot Size

ApplicationLotsSharesAmount
Retail (Min)120₹14,820
Retail (Max)13260₹1,92,660
S-HNI (Min)14280₹2,07,480
S-HNI (Max)671340₹9,92,940
B-HNI (Min)681360₹10,07,760

Concord Biotech Limited Promoter Holding

Sudhir Vaid and Ankur Vaid are the Company Promoters.

Pre Issue Share HoldingPost Issue Share Holding
4.08%44.08%
Key Performance Indicator

Concord Biotech IPO Market Cap is Rs 7752.06 Cr and P/E (x) is 32.29.

KPIValues
ROE20.06%
ROCE24.27%
RoNW20%
Pre IPOPost IPO
EPS (Rs)32.2920.79
P/E (x) 32.2920.79

Concord Biotech Limited COMPANY INFORMATION

Concord Biotech IPO is a Book Built Issue. The IPO total issue size is Rs 1,551.00 Cr. The Concord Biotech IPO price is ₹705 to ₹741 per share. The IPO will list on BSE, NSE.

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan. The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider. Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.

FAQs About Concord Biotech Limited

Concord Biotech Limited will open on 04 Aug, 2023 and close on 08 Aug, 2023. Investors must apply within this period to participate.

The Concord Biotech Limited price band is set between ₹705.00 and ₹741.00 per share. The minimum lot size is 20, requiring an investment of at least ₹14820.00.

The Concord Biotech Limited shares are expected to be listed on 18 Aug, 2023, subject to regulatory approvals and final allotment.

You can track your Concord Biotech Limited application status on the registrar’s website: Link Intime or KFintech using your PAN, application number, or DP ID

The Concord Biotech Limited will be listed on major stock exchanges such as NSE and BSE, where you can trade shares once they are listed.